The Placebo Effect in Rare Disease Clinical Trials: Measurement, Impact, and Statistical Approaches for Patient-as-Own-Control Designs
Single-arm trial designs are scientifically sound for rare diseases when outcomes are objective, potentially accelerating treatments for underserved populations.
A systematic analysis by former FDA CDER head Janet Woodcock demonstrates that the placebo objection to patient-as-own-control trial designs in rare disease is manageable rather than disqualifying, as objective endpoints show near-zero placebo effects (SMD<0.10) and subjective endpoints can be corrected with established analytical tools. This provides important regulatory and methodological support for expanding single-arm/own-control designs to advance rare disease drug development where RCTs are often impractical.
What the study was
- Study design
- Systematic methodology review with meta-analysis of placebo effects by endpoint type
- Population
- Rare disease clinical trial participants; analysis of objective vs subjective endpoints
- Category
- Other
- Maturity
- Validated
- Journal
- Clinical and Translational Science
Why it surfaced
Rare disease drug development methodology contribution with direct regulatory implications; co-authored by former FDA CDER director; provides evidence-based support for expanding viable trial designs in rare diseases.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.